RESUMEN
Microdose study enables us to understand the pharmacokinetic profiles of drugs in humans prior to the conventional clinical trials. The advantage of microdose study is that the unexpected pharmacological/toxicological effects of drugs caused by drug interactions or genetic polymorphisms of metabolic enzymes/transporters can be avoided due to the limited dose. With a combination use of accelerator mass spectrometry (AMS) and (14)C-labaled compounds, the pharmacokinetics of both parent drug and its metabolites can be sensitively monitored. Thus, to demonstrate the usability of microdose study with AMS for the prediction of the impact of genetic polymorphisms of CYP enzyme on the pharmacokinetics of unchanged drugs and metabolites, we performed microdose pharmacogenetic study using tolbutamide as a CYP2C9 probe drug. A microdose of (14)C-tolbutamide (100 µg) was administered orally to healthy volunteers with the CYP2C9(∗)1/(∗)1 or CYP2C9(∗)1/(∗)3 diplotype. Area under the plasma concentration-time curve for the (14)C-radioactivity, determined by AMS, or that for the parent drug, determined by liquid chromatography/mass spectrometry, was about 1.6 times or 1.7 times greater in the CYP2C9(∗)1/(∗)3 than in the CYP2C9(∗)1/(∗)1 group, which was comparable to the previous reports at therapeutic dose. In the plasma and urine, tolbutamide, carboxytolbutamide, and 4-hydroxytolbutamide were detected and practically no other metabolites could be found in both diplotype groups. The fraction of metabolites in plasma radioactivity was slightly lower in the CYP2C9(∗)1/(∗)3 group. Microdose study can be used for the prediction of the effects of genetic polymorphisms of enzymes on the pharmacokinetics and metabolic profiles of drugs with minimal care of their pharmacological/toxicological effects.
Asunto(s)
Hidrocarburo de Aril Hidroxilasas/genética , Hipoglucemiantes/farmacocinética , Tolbutamida/farmacocinética , Adulto , Hidrocarburo de Aril Hidroxilasas/metabolismo , Radioisótopos de Carbono/administración & dosificación , Radioisótopos de Carbono/sangre , Radioisótopos de Carbono/farmacocinética , Radioisótopos de Carbono/orina , Citocromo P-450 CYP2C9 , Heces/química , Genotipo , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/sangre , Hipoglucemiantes/orina , Masculino , Espectrometría de Masas/métodos , Persona de Mediana Edad , Polimorfismo Genético , Tolbutamida/administración & dosificación , Tolbutamida/sangre , Tolbutamida/orina , Adulto JovenRESUMEN
OBJECTIVE: The guidelines for microdosing in clinical trials were published in Japan in 2008 following the guidelines of the European Medicines Agency and the Food and Drug Administration. They recommend utilizing accelerator mass spectrometry (AMS) and positron emission tomography as candidates for monitoring drug metabolites in preclinical studies. We correlate the two methods by measuring appropriately labeled tissue samples from various mouse organs using both AMS and gamma counter. METHODS: First, we measured the (14)C background levels in mouse organs using the AMS system. We then clarified the relationship between AMS and gamma counter by simultaneously administering (14)C-2-fluoro-2-deoxyglucose ((14)C-FDG) and (18)F-2-fluoro-2-deoxyglucose ((18)F-FDG). Tissue distribution was examined after 30 min, 1 h, 2 h and 4 h using the AMS system for (14)C-FDG and gamma counter for (18)F-FDG. Background (14)C levels were subtracted from the data obtained with radiotracer administration. RESULTS: The background (14)C concentration differed with tissue type measured. Background (14)C concentration in mouse liver was higher than in other organs, and was approximately 1.5-fold that in blood. The correlation coefficient (r) of the measurements between AMS ((14)C-FDG) and gamma counter ((18)F-FDG) was high in both normal (0.99 in blood, 0.91 in brain, 0.61 in liver and 0.78 in kidney) and tumor-bearing mice (0.95 in blood and 0.99 in tumor). The clearance profile of (18)F-FDG was nearly identical to that of (14)C-FDG measured with AMS. CONCLUSIONS: Accelerator mass spectrometry analysis has an excellent correlation with biodistribution measurements using gamma counter. Our results suggest that the combination of AMS and PET can act as a complementary approach to accelerate drug development.
Asunto(s)
Rayos gamma , Espectrometría de Masas/estadística & datos numéricos , Tomografía de Emisión de Positrones/estadística & datos numéricos , Animales , Radioisótopos de Carbono , Línea Celular Tumoral , Femenino , Fluorodesoxiglucosa F18 , Humanos , Ratones , Neoplasias/diagnóstico por imagenRESUMEN
A technique utilizing simultaneous intravenous microdosing of (14)C-labeled drug with oral dosing of non-labeled drug for measurement of absolute bioavailability was evaluated using R-142086 in male dogs. Plasma concentrations of R-142086 were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and those of (14)C-R-142086 were measured by accelerator mass spectrometry (AMS). The absence of metabolites in the plasma and urine was confirmed by a single radioactive peak of the parent compound in the chromatogram after intravenous microdosing of (14)C-R-142086 (1.5 microg/kg). Although plasma concentrations of R-142086 determined by LC-MS/MS were approximately 20% higher than those of (14)C-R-142086 as determined by AMS, there was excellent correlation (r=0.994) between both concentrations after intravenous dosing of (14)C-R-142086 (0.3 mg/kg). The oral bioavailability of R-142086 at 1 mg/kg obtained by simultaneous intravenous microdosing of (14)C-R-142086 was 16.1%, this being slightly higher than the value (12.5%) obtained by separate intravenous dosing of R-142086 (0.3 mg/kg). In conclusion, on utilizing simultaneous intravenous microdosing of (14)C-labeled drug in conjunction with AMS analysis, absolute bioavailability could be approximately measured in dogs, but without total accuracy. Bioavailability in humans may possibly be approximately measured at an earlier stage and at a lower cost.
Asunto(s)
Radioisótopos de Carbono/sangre , Radioisótopos de Carbono/orina , Plasma/química , Espectrometría de Masa por Ionización de Electrospray/métodos , Administración Oral , Amidinas/sangre , Amidinas/farmacocinética , Amidinas/orina , Animales , Disponibilidad Biológica , Radioisótopos de Carbono/química , Radioisótopos de Carbono/farmacocinética , Cromatografía Líquida de Alta Presión , Perros , Evaluación Preclínica de Medicamentos , Estudios de Evaluación como Asunto , Femenino , Inyecciones Intravenosas , Masculino , Espectrometría de Masas/métodos , Sulfonamidas/sangre , Sulfonamidas/farmacocinética , Sulfonamidas/orinaRESUMEN
OBJECTIVE: Phase 0 clinical studies, which are known as microdose trials, are expected to promote drug development and reduce development costs. The accelerator mass spectrometry (AMS) system is expected to play an important role in the microdosing tests, as it is a highly sensitive measurement system that can be used to determine the drug concentrations in these tests. Using the AMS system, we measured the background (14)C-concentration in human blood and evaluated the data for use as a reference in microdose studies that administer (14)C-labeled compounds in humans. METHODS: Blood samples of five healthy Japanese volunteers (three men, two women, median age 40.4 +/- 9.8 years) were collected around the same time and just prior to when the subjects ate a meal (between 12:00 noon and 2:00 pm). Centrifugal separations of blood that was allowed to clot and the plasma were performed at 503 g for 2 min at 4 degrees C. Background (14)C-concentration for each of the samples was measured using the AMS system. The Institute of Accelerator Analysis, which is the first contract research organization in Japan that is capable of providing AMS analysis services for carbon dating and bioanalysis work, performed the AMS analysis. RESULTS: The mean (14)C-concentration in blood was 1.613 +/- 0.125 dpm/ml (men 1.668 +/- 0.114 dpm/ml, women 1.514 +/- 0.076 dpm/ml), in clots 2.373 +/- 0.087 dpm/ml (men 2.381 +/- 0.101 dpm/ml, women 2.357 +/- 0.060 dpm/ ml), and in plasma 0.648 +/- 0.049 dpm/ml (men 0.647 +/- 0.059 dpm/ml, women 0.649 +/- 0.032 dpm/ml). The coefficient variation (CV) for blood was 7.8% (men 6.9%, women 5.0%), for clots 3.7% (men 4.3%, women 2.5%), and for plasma 7.6% (men 9.1%, women 4.9%). The (14)C-concentrations of the clot and blood were higher than those of plasma. The (14)C-concentrations in the blood and plasma were slightly different between individuals when compared with the values for the clot, although the differences were quite small, with a CV value less than 7.8%. CONCLUSIONS: Even though the (14)C-concentration differed only slightly between individuals, (14)C-concentrations of the clot and blood were higher than those of the plasma. Therefore, the variation and difference of the background data for blood and plasma might be of use as a reference for microdosing test evaluations.